The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support

Kerolos Wagdy

Abstract


[no abstract - showing first paragraph]

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic medication that are well established for the management of type-2 diabetes mellitus (DM). They have a unique mechanism of action that targets the kidneys through inhibition of 90% of glucose reabsorption.


Full Text:

PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Kerolos Wagdy

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.